Baird Financial Group, Inc. Eagle Pharmaceuticals, Inc. Transaction History

Baird Financial Group, Inc.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$37.02 - $51.28 $1.36 Million - $1.88 Million	-36,747 Closed	0 $0
Q2 2020 Oct 22, 2020	BUY	$43.24 - $55.02 $57,811 - $73,561	1,337 Added 3.78%	36,747 $1.76 Million
Q2 2020 Aug 14, 2020	SELL	$43.24 - $55.02 $18,463 - $23,493	-427 Reduced 1.19%	35,410 $2.13 Million
Q1 2020 May 14, 2020	BUY	$34.37 - $60.07 $3,024 - $5,286	88 Added 0.25%	35,837 $1.65 Million
Q4 2019 Feb 14, 2020	BUY	$54.32 - $64.31 $223,092 - $264,121	4,107 Added 12.98%	35,749 $2.15 Million
Q3 2019 Nov 14, 2019	BUY	$53.25 - $59.98 $64,432 - $72,575	1,210 Added 3.98%	31,642 $1.79 Million
Q2 2019 Aug 14, 2019	SELL	$46.61 - $58.45 $77,046 - $96,617	-1,653 Reduced 5.15%	30,432 $1.7 Million
Q1 2019 May 14, 2019	SELL	$38.66 - $51.82 $80,374 - $107,733	-2,079 Reduced 6.09%	32,085 $1.62 Million
Q4 2018 Feb 14, 2019	SELL	$36.72 - $67.73 $3,194 - $5,892	-87 Reduced 0.25%	34,164 $1.38 Million
Q3 2018 Nov 13, 2018	BUY	$66.65 - $83.86 $32,591 - $41,007	489 Added 1.45%	34,251 $2.32 Million
Q2 2018 Aug 13, 2018	BUY	$51.25 - $76.62 $2,255 - $3,371	44 Added 0.13%	33,762 $2.55 Million
Q1 2018 May 14, 2018	BUY	$52.16 - $66.86 $5,476 - $7,020	105 Added 0.31%	33,718 $1.78 Million
Q4 2017 Feb 09, 2018	SELL	$49.6 - $60.87 $5,158 - $6,330	-104 Reduced 0.31%	33,613 $1.8 Million
Q3 2017 Nov 14, 2017	SELL	$46.62 - $60.36 $7,925 - $10,261	-170 Reduced 0.5%	33,717 $2.01 Million
Q2 2017 Aug 14, 2017	BUY	N/A	33,887	33,887 $2.67 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Baird Financial Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Baird Financial Group, Inc. with notifications on news.